Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cairo University
• Treatments: Cortisol succinate; Cyclophosphamide; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Adult systemic lupus erythematosis patients

Exclusion Criteria:

• Patients younger than 18 years, patients with other autoimmune diseases or malignancy.